Compare EE & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EE | IVA |
|---|---|---|
| Founded | 2003 | 2011 |
| Country | United States | France |
| Employees | 1046 | 77 |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2022 | N/A |
| Metric | EE | IVA |
|---|---|---|
| Price | $35.79 | $5.40 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $39.20 | $16.20 |
| AVG Volume (30 Days) | ★ 362.3K | 254.3K |
| Earning Date | 05-06-2026 | 03-30-2026 |
| Dividend Yield | ★ 0.96% | N/A |
| EPS Growth | ★ 0.79 | N/A |
| EPS | ★ 0.37 | N/A |
| Revenue | ★ $1,228,263,000.00 | N/A |
| Revenue This Year | $23.59 | N/A |
| Revenue Next Year | $24.37 | $751.20 |
| P/E Ratio | $97.89 | ★ N/A |
| Revenue Growth | ★ 44.26 | N/A |
| 52 Week Low | $21.29 | $2.94 |
| 52 Week High | $43.18 | $7.98 |
| Indicator | EE | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 55.89 | 48.36 |
| Support Level | $35.10 | $4.98 |
| Resistance Level | $43.18 | $6.42 |
| Average True Range (ATR) | 1.44 | 0.24 |
| MACD | 0.26 | 0.05 |
| Stochastic Oscillator | 80.54 | 44.54 |
Excelerate Energy Inc. offers comprehensive LNG solutions by providing integrated services throughout the LNG value chain. The company delivers a full range of regasification services, including Floating Storage and Regasification Units (FSRUs), infrastructure development, and the supply of LNG and natural gas. With operational presence in several countries - Argentina, Bangladesh, Brazil, Finland, Germany, Pakistan, the United Arab Emirates (UAE), and the United States. The company generates revenue through Terminal Services, as well as from LNG, gas, and power. These revenues are derived from its vertically integrated activities in LNG sourcing, transportation, regasification, and power generation.
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.